【聚焦】婦科中藥新藥來襲，200億市場風雲再起

米內網

2025/07/17

精彩內容7月16日，合肥華潤神鹿藥業提交了宣鬱通經湯顆粒中藥3.1類新藥上市申請獲得CDE承辦。宣鬱通經湯出自《傅青主女科》捲上，合肥華潤神鹿藥業為首家報產。近幾年，華潤醫藥在中藥經典名方領域收穫滿滿，已累計拿下了4個新藥，5款新藥報產在審。圖1：合肥華潤神鹿藥業最新申報的中藥新藥來源：CDE官網據悉，宣鬱通經湯出自《傅青主女科》捲上，具有補肝血，解肝鬱，利肝氣，降肝火之功效，主治婦人經前腹疼數日...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2552910423"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552910423\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552910423?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-17 16:04","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2552910423","market":"sh","top_or_hot":-1,"title":"【聚焦】婦科中藥新藥來襲，200億市場風雲再起","media":"米內網","content":"<div>\n<p>精彩內容7月16日，合肥華潤神鹿藥業提交了宣鬱通經湯顆粒中藥3.1類新藥上市申請獲得CDE承辦。宣鬱通經湯出自《傅青主女科》捲上，合肥華潤神鹿藥業為首家報產。近幾年，華潤醫藥在中藥經典名方領域收穫滿滿，已累計拿下了4個新藥，5款新藥報產在審。圖1：合肥華潤神鹿藥業最新申報的中藥新藥來源：CDE官網據悉，宣鬱通經湯出自《傅青主女科》捲上，具有補肝血，解肝鬱，利肝氣，降肝火之功效，主治婦人經前腹疼數日...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717160921a45084bd&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【聚焦】婦科中藥新藥來襲，200億市場風雲再起</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【聚焦】婦科中藥新藥來襲，200億市場風雲再起\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">米內網</strong><span class=\"h-time small\">2025-07-17 16:04</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>精彩內容7月16日，合肥華潤神鹿藥業提交了宣鬱通經湯顆粒中藥3.1類新藥上市申請獲得CDE承辦。宣鬱通經湯出自《傅青主女科》捲上，合肥華潤神鹿藥業為首家報產。近幾年，華潤醫藥在中藥經典名方領域收穫滿滿，已累計拿下了4個新藥，5款新藥報產在審。圖1：合肥華潤神鹿藥業最新申報的中藥新藥來源：CDE官網據悉，宣鬱通經湯出自《傅青主女科》捲上，具有補肝血，解肝鬱，利肝氣，降肝火之功效，主治婦人經前腹疼數日...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717160921a45084bd&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717160921a45084bd&s=b\">米內網</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01109","symbol_name":"華潤置地","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717160921a45084bd&s=b","article_id":"2552910423","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717160921a45084bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2552910423","pubTimestamp":1752739465,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"精彩內容7月16日，合肥華潤神鹿藥業提交了宣鬱通經湯顆粒中藥3.1類新藥上市申請獲得CDE承辦。宣鬱通經湯出自《傅青主女科》捲上，合肥華潤神鹿藥業為首家報產。近幾年，華潤醫藥在中藥經典名方領域收穫滿滿，已累計拿下了4個新藥，5款新藥報產在審。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"561510":"中药ETF华泰柏瑞","562390":"中药ETF银华","01109":"华润置地","03320":"华润医药"},"translate_title":"[Focus] New gynecological traditional Chinese medicine drugs are coming, and the 20 billion market is revived","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"561510":0.9,"562390":0.9,"01109":0.9,"03320":0.9},"content_text":"精彩內容7月16日，合肥華潤神鹿藥業提交了宣鬱通經湯顆粒中藥3.1類新藥上市申請獲得CDE承辦。宣鬱通經湯出自《傅青主女科》捲上，合肥華潤神鹿藥業為首家報產。近幾年，華潤醫藥在中藥經典名方領域收穫滿滿，已累計拿下了4個新藥，5款新藥報產在審。圖1：合肥華潤神鹿藥業最新申報的中藥新藥來源：CDE官網據悉，宣鬱通經湯出自《傅青主女科》捲上，具有補肝血，解肝鬱，利肝氣，降肝火之功效，主治婦人經前腹疼數日，而後經水行，經來多紫黑塊，症見月經不調、行經腹痛、經有血塊，臨床常用於治療婦女月經不調、慢性盆腔炎、子宮內膜炎、功能性子宮出血等疾病。米內網數據顯示，合肥華潤神鹿藥業是宣鬱通經湯顆粒首家報產企業。圖2：中成藥婦科用藥的銷售情況（單位：萬元）來源：米內網格局數據庫在中國三大終端六大市場（統計範圍見文末），中成藥#婦科用藥在2021-2024年穩步增長，2024年達到了200億元，#華潤醫藥是TOP12集團（一級）。表1：2024年華潤醫藥中成藥婦科用藥TOP10產品注：銷售額低於1000萬元用*表示來源：米內網格局數據庫華潤醫藥最暢銷的中成藥婦科用藥是獨家產品舒肝顆粒，2024年在中國三大終端六大市場的銷售額接近1.8億元，此外，獨家產品安宮止血顆粒和雙橘顆粒2024年分別大漲了18.81%、356.59%，潛力不容小覷。表2：華潤醫藥獲批及報產在審的中藥經典名方來源：米內網中國申報進度（MED）數據庫","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}